Regeneron Pharmaceuticals Inc. (REGN)
NASDAQ
$953.89
+$2.56
(+0.27%)
Regular Market
Regeneron Pharmaceuticals Inc. (REGN) Live Price Chart
Last updated: 2026-11-13 16:42:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $953.89, with a market capitalization of $98.40B and a P/E ratio of 20.43. Over the past 52 weeks, its price has ranged from $591.52 to $991.73. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$98.40B | |
$952.47 | |
$967.92 | |
$942.90 | |
$951.19 | |
160.34K | |
783.63K | |
20.43 | |
$991.73 | |
$591.52 | |
0.39% | |
12-31 |
Regeneron Pharmaceuticals Inc. (REGN) Stock Price Today
Regeneron Pharmaceuticals Inc. (REGN) is currently trading at $953.89 as of 2026-11-13 16:41:00, up 0.27% ($2.56) from the previous close of $951.19
During today's regular trading session, REGN has traded between $942.90 and $967.92, with a trading volume of 160.34K shares. The current price is near the middle of today's range.
Regeneron Pharmaceuticals Inc. (REGN) 7-Day Stock Price Change
Over the past seven days, Regeneron Pharmaceuticals Inc. (REGN) moved from $902.90 to $953.89, representing a gain of 5.65% ($50.99).
The stock traded between $887.04 and $981.55 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 906.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
REGN 52-Week Price Position
Position in Range: 90.5%
52W Low$591.52
52W High$991.73
REGN is currently trading at $953.89, placing it 90.5% of the way from its 52-week low of $591.52 to its 52-week high of $991.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Regeneron Pharmaceuticals Inc. (REGN)?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15,410 |
| CEO | Leonard S. Schleifer |
| Founded | 1988 |
| Exchange | NASDAQ |
| Company Website |
REGN Stock Events
View the latest dividend and stock split events for Regeneron Pharmaceuticals Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 20, 2026 |
| Payment Date | Dec 3, 2026 |
| Dividend Per Share | $0.94 |
REGN News
Latest news related to Regeneron Pharmaceuticals Inc. and REGN stock.
- BenzingaRead Full Article
- BenzingaRead Full Article
If You Invested $1000 In Regeneron Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 8.79% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceuticals has a market
- MassiveRead Full Article
BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
- MassiveRead Full Article
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Regeneron Pharmaceuticals (REGN) shares surged 27.4% over the past month, driven by strong third-quarter results. Eylea HD sales jumped 62% to $699 million, offsetting declining Eylea sales amid competition from Roche's Vabysmo. Strong Dupixent profits, oncology portfolio expansion, and a promising pipeline including cemdisiran for myasthenia gravis support long-term growth. The stock trades at an attractive valuation of 13.29X forward earnings, below historical and industry averages, earning a Zacks Rank #2 (Buy) rating.
Ways to Trade REGN at MEXC
How to Buy Regeneron Pharmaceuticals Inc. (REGN) Stock on MEXC
Eligible investors can buy real shares of Regeneron Pharmaceuticals Inc. (REGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for REGN and Place Your Order
Open the RealStocks trading page and search for REGN. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.
Frequently Asked Questions (FAQ)
1.What is Regeneron Pharmaceuticals Inc. (REGN) stock price today?
Regeneron Pharmaceuticals Inc. (REGN) is currently trading at $953.89, up 0.27% ($2.56) from the previous close of $951.19. Intraday prices update in real time during regular trading hours.
2.Is REGN stock going up or down today?
As of 2026-11-13 16:41:00, REGN is trading at $953.89, up 0.27% ($2.56) from its previous close of $951.19. The stock has traded between $942.90 and $967.92 during today’s regular session. Past price movements do not guarantee future results.
3.What is REGN pre-market price?
As of 2026-11-13 16:41:00, REGN is trading at $960.50 in pre-market trading, up 0.98% ($9.31) from the previous close of $951.19. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is REGN after-hours price?
As of 2026-11-13 16:41:00, REGN is trading at $953.58 in after-hours trading, down 0.03% ($0.31) from the regular-session close of $953.89. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is REGN stock trading now?
REGN trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does REGN sit relative to its 52-week high and low?
Over the past 52 weeks, REGN has traded between a low of $591.52 and a high of $991.73. At $953.89, the stock is positioned 90.5% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Regeneron Pharmaceuticals Inc. in?
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Regeneron Pharmaceuticals Inc.'s market capitalization and where is it listed?
Regeneron Pharmaceuticals Inc. is listed on the NASDAQ exchange with a market capitalization of $98.40B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is REGN valued in terms of P/E ratio and EPS?
REGN trades at a P/E ratio of 20.43, based on trailing-twelve-month EPS of $46.57. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Regeneron Pharmaceuticals Inc. pay a dividend?
Regeneron Pharmaceuticals Inc. pays an indicated annual cash dividend of $3.72 per share, with a current dividend yield of 0.39% based on the latest share price. Dividend policies are subject to change at the board's discretion.
Explore More US Stocks
Stocks in the Same Sector
Browse other US stocks in the same sector as Regeneron Pharmaceuticals Inc.
Largest Market Cap
See US stocks with the highest market capitalization
Most Actively Traded
Discover today's most actively traded US stocks
Top Gainers
Browse today's leading gainers in the US stock market
Top 5 Cryptocurrencies
Explore the cryptocurrencies with the highest market capitalization
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to REGN, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
REGN Stock Calculator
Estimate the value between REGN shares and USD.
REGN Shares to USD
REGN Shares
REGN
USD
USD
1.00 REGN shares = 953.89 USD
Calculations are estimates based on the latest available price and are for reference only.